OSSIO

OSSIO Overview

OSSIO is an orthopedic company providing an innovative alternative to metal implants in the more than $10 billion orthopedic fixation market with its intelligent bone implant technology. OSSIOfiber is a biofriendly implant material that is stronger than cortical bone and leaves nothing permanent behind. Stemming from years of biomechanical research and a vision for the possibility of better bone healing, OSSIOfiber is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse inflammation. OSSIOs proprietary technology can address many surgical applications through the manufacture of endless implant designs. In addition, OSSIOfiber implants utilize existing reimbursement and surgical techniques.

Cumulative Funding Raised Over Time ($)

Latest News

Dec 2, 2024 · www.businesswire.com

OSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues

Oct 18, 2022 · www.finsmes.com

growth-positive

Ossio Closes $38.5M Series C Financing

Ossio, an orthopedic fixation technology company, has raised $38.5M in Series C funding led by MVM Partners. The funding will be used to strengthen awareness for the patient benefits of OSSIOfiber implants and accelerate new product platforms in the major orthopedic fixation markets. Ossio leverages the OSSIOfiber Intelligent Bone Regeneration Technology to create implants made from a proprietary mineral fiber matrix held together by a naturally degradable polymer. The company has already used over 10,000 OSSIOfiber implants in orthopedic surgeries since 2019.

Investment

Aug 8, 2022 · www.businesswire.com

OSSIO Announces U.S. Launch and First Commercial Use of OSSIOfiber® Suture Anchors, Expanding Patient Access to Growing Portfolio of Bio-Integrative Orthopedic Fixation Technology

Mar 29, 2022 · www.businesswire.com

Growth-Positive

OSSIO Achieves Third FDA Clearance in 4 Months for OSSIOfiber® Implants; Prepares to Expand Patient Access to Bio-Integrative Orthopedic Fixation Technology Portfolio in Q2/Q3

Orthopedic fixation technology start-up OSSIO has received its third regulatory clearance from the U.S. Food and Drug Administration (FDA) for its OSSIOfiber product family. The clearance will allow the company to expand patient and surgeon access to additional implants made from OSSIOfiber Intelligent Bone Regeneration Technology over the next six months. The company has already achieved significant market penetration in the United States, with more than 6,000 implantations of OSSIOfiber products performed to date. The recent FDA clearances are expected to increase the uptake of OSSIOs growing portfolio of bio-integrative products.

CustomersExpand

Mar 3, 2022 · www.odtmag.com

growth-positive

OSSIO Wins GPO Contract for Bio-Integrative Fixation Tech

OSSIO Inc. has expanded its OSSIOfiber product line through a three-year contract with Vizient. The contract enables increased access to OSSIOfiber technology for thousands of U.S. hospitals and surgery centers. The OSSIOfiber products are designed for rapid bone in-growth, regeneration, and replacement, providing durable fixation and natural healing. The contract covers the OSSIOfiber Intelligent Bone Regeneration Technology portfolio, including hammertoe fixation systems, trimmable fixation nails, and compression screws. The products are now available to all members of Vizient at negotiated pricing. OSSIO aims to provide a credible replacement to metal implants in the orthopedic fixation market.

Customers

Funding

Team Members

3

Employees: 51-200

Web & Social Links

Locations

HaTohen Street 8, Caesarea, Israel

300 Tradecenter Drive, Woburn, MA, USA

Photos & Videos

1 item(s)

OSSIO Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info